Top Image: Cytospin smear from a patient with myelodysplasia with megakaryocytic with 3 separate nuclei (so-called "pawn ball" megakaryocyte).

Welcome

MDS, a heterogeneous group of diseases of the blood and bone marrow, occurs at an average rate of 4.8 cases per 100,000 people in the United States. Between 2006 and 2010 there were an estimated 14,123 new cases of MDS throughout the nation per year.1

There are many complexities associated with this disease the multispecialty team must address as a clinical care unit. They include obtaining adequate bone marrow specimens, identification and classification of MDS, the comorbidity rate of MDS patients and the decision-making process for treatment.

To address the educational gaps associated with these complexities, the American Society for Clinical Pathology (ASCP) and the American Society of Hematology (ASH) have designed a comprehensive MDS-directed educational curriculum that includes a live workshop event, CheckPath case studies, and Multimedia Case Studies titled, This DC3-MDS website is uniquely designed to facilitate access to education and resources.

Myelodysplastic Syndrome/Acute Myeloid Leukemia With t(3;21)(q26.2;q22) Is Commonly a Therapy-Related Disease Associated With Poor Outcome Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes Myelodysplastic Syndrome From Normal Bone Marrow
Shaoying Li, MD, C. Cameron Yin, MD, PhD, L. Jeffrey Medeiros, et al. Sara A. McClintock-Treep, Robert C. Briggs, Keith E. Shults, et al.
This study focused on 17 patients with MDS/AML associated with t(3;21) and compared them with 17 patients with MDS associated with inv(3) (q21q26.2)/t(3;3)(q21;q26.2), because these entities share 3q26 locus abnormalities. All patients died, with 1- and 2-year survival rates of 35% and 6%, respectively. Although multilineage dysplasia and frequent association with −7/7q were similar in both groups, MDS/AML cases associated with t(3;21) have a higher frequency of therapy-related disease and shorter survival times, suggesting that they are distinct from MDS/AML cases associated with inv(3)/t(3;3). By using flow cytometry, this study analyzed myeloid nuclear differentiation antigen (MNDA) expression in myeloid precursors in bone marrow from patients with myelodysplastic syndrome (MDS) and control samples from patients undergoing orthopedic procedures. Correlation of MNDA-dim levels with World Health Organization 2008 morphologic diagnoses was not significant (P = .21), but correlation with patient International Prognostic Scoring System scores suggested a trend (P = .07). Flow cytometric assessment of MNDA in myeloid precursors in bone marrow may be useful for the diagnosis of MDS.

You can help contribute to better outcomes of future MDS patients by responding to this survey:

Take Survey
http://survey.highroadsolution.com/f/736732/56d7/

You will not be asked to give your name or contact information. Information is for research purposes only and will not be shared with any commercial companies associated with this project.

Supported by an educational grant from Celgene.




Reference

1Leukemia & Lymphoma Society. Facts 2013. Available at:
http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf. Accessed January 4, 2014.